AKT1 and neoplasm: In line with in vitro findings, CZ415 plus MEK162 co-administration led to in-activation of mTORC1/2 (p-S6K1/p-AKT Ser473) and ERK (p-ERK1/2) in U2OS tumor tissues (Figure 6D).